MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
109 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Medizinische Universitat Innsbruck
Innsbruck, Austria
- Akh Allgemeines Krankenhaus Der Stadt Linz
Linz, Austria
- Medical University of Vienna
Vienna, Austria
- Gza Ziekenhuizen - Campus Sint-Augustinus
Antwerp, Belgium
- University Hospital Antwerp
Antwerp, Belgium
- Cliniques Universitaires Saint-Luc
Brussels, Belgium
- Clinique Saint-Joseph
Liège, Belgium
- London Regional Cancer Center
London, Ontario, Canada
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
- University of Alberta- Cross Cancer Institute
Edmonton, Canada
- Mcgill University Health Center
Québec, Canada
- Motol University Hospital
Prague, Czechia
- Institut de Cancerologie de L'Ouest Site Paul Papin
Angers, France
- Centre Léon Bérard
Lyon, France
- Hopital de L'Institut Curie
Paris, France
- Institut de Cancerologie de L'Ouest
Saint-Herblain, France
- Institut Claudius Regaud
Toulouse, France
- Universitatsklinikum Des Saarlandes
Homburg, Germany
- Universitätsklinikum Schleswig-Holstein
Lübeck, Germany
- Interdisziplinares Onkologisches Zentrum
Munich, Germany
- Istituto Clinico Humanitas
Rozzano, Milan, Italy
- Centro Riferimento Oncologico, Irccs, Istituto Nazionale Tumori
Aviano, Italy
- Azienda Ospedaliero-Universitaria Di Bologna
Bologna, Italy
- Azienda Socio Sanitaria Territoriale Di Cremona
Cremina, Italy
- Istituto Europeo Di Oncologia
Milan, Italy
- Istituto Nazionale Tumori, Irccs Fondazione G. Pascale
Naples, Italy
- Instituto Oncologico Veneto Irccs
Padova, Italy
- Oncology Unit Macerata Hospital
Province of Macerata, Italy
- Azienda Ospedaliero S. Maria Di Terni
Terni, Italy
- Hospital Universitario Vall D'Hebron
Barcelona, Spain
- Hospital San Pedro de Alcantara
Cáceres, Spain
- Hospital Universitario Reina Sofía
Córdoba, Spain
- Hospital Universitario Arnau de Vilanova
Lleida, Spain
- Hospital Clinico San Carlos
Madrid, Spain
- Hospital General Universitario Gregorio Marañón
Madrid, Spain
- Hospital Universitario Ramon Y Cajal
Madrid, Spain
- H.U.Son Espases
Palma de Mallorca, Spain
- Hospital de Navarra
Pamplona, Spain
- Hospital Universitario Virgen de la Macarena
Seville, Spain
- Palo Verde Cancer Center
Glendale, Arizona, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2014
- Primary completion
- 31 Dec 2016
- Completion
- 30 Jun 2017
- Last update posted
- 6 Jan 2017
- Registered enrollment
- 113
- Registry id
- NCT02213744
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.